202 related articles for article (PubMed ID: 2168792)
1. [Experimental research on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonian animal models in the rhesus monkey and C57 black mouse].
Chen S
Zhonghua Yi Xue Za Zhi; 1990 May; 70(5):252-4, 18. PubMed ID: 2168792
[TBL] [Abstract][Full Text] [Related]
2. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
3. Hemiparkinsonism in monkeys following unilateral common carotid artery infusion of MPTP. A study of behavior, biochemistry and histology.
Chen SD; Zhou XD; Xu DL; Li GW; Tang QM; Xu XR
Chin Med J (Engl); 1991 Sep; 104(9):758-63. PubMed ID: 1935358
[TBL] [Abstract][Full Text] [Related]
4. Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains.
Haobam R; Sindhu KM; Chandra G; Mohanakumar KP
Behav Brain Res; 2005 Sep; 163(2):159-67. PubMed ID: 15941598
[TBL] [Abstract][Full Text] [Related]
5. Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey.
Pifl C; Schingnitz G; Hornykiewicz O
Neuroscience; 1991; 44(3):591-605. PubMed ID: 1754053
[TBL] [Abstract][Full Text] [Related]
6. MRI detects acute degeneration of the nigrostriatal dopamine system after MPTP exposure in hemiparkinsonian monkeys.
Miletich RS; Bankiewicz KS; Quarantelli M; Plunkett RJ; Frank J; Kopin IJ; Di Chiro G
Ann Neurol; 1994 Jun; 35(6):689-97. PubMed ID: 8210225
[TBL] [Abstract][Full Text] [Related]
7. N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the monkey: neurochemical pathology and regional brain metabolism.
Mitchell IJ; Cross AJ; Sambrook MA; Crossman AR
J Neural Transm Suppl; 1986; 20():41-6. PubMed ID: 3462325
[TBL] [Abstract][Full Text] [Related]
8. [Parkinsonism induced by MPTP as an experimental model of Parkinson disease: similarities and differences].
Luquin MR; Obeso JA; Herrero MT; Laguna J; Martínez-Lage JM
Neurologia; 1991 Oct; 6(8):287-94. PubMed ID: 1790005
[TBL] [Abstract][Full Text] [Related]
9. [A mouse model of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced parkinsonism: effect of norepinephrine terminal destruction].
Nishi K; Kondo T; Narabayashi H
No To Shinkei; 1987 Jul; 39(7):663-72. PubMed ID: 3314916
[TBL] [Abstract][Full Text] [Related]
10. Dopamine turnover is upregulated in the caudate/putamen of asymptomatic MPTP-treated rhesus monkeys.
Pifl C; Hornykiewicz O
Neurochem Int; 2006 Oct; 49(5):519-24. PubMed ID: 16698121
[TBL] [Abstract][Full Text] [Related]
11. Effect of age on markers for monoaminergic neurons of normal and MPTP-lesioned rhesus monkeys: a multi-tracer PET study.
Doudet DJ; Rosa-Neto P; Munk OL; Ruth TJ; Jivan S; Cumming P
Neuroimage; 2006 Mar; 30(1):26-35. PubMed ID: 16378735
[TBL] [Abstract][Full Text] [Related]
12. Involvement of cytochrome P450 2E1 in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease.
Vaglini F; Pardini C; Viaggi C; Bartoli C; Dinucci D; Corsini GU
J Neurochem; 2004 Oct; 91(2):285-98. PubMed ID: 15447662
[TBL] [Abstract][Full Text] [Related]
13. Modeling neurodegenerative diseases in vivo review.
von Bohlen Und Halbach O
Neurodegener Dis; 2005; 2(6):313-20. PubMed ID: 16909014
[TBL] [Abstract][Full Text] [Related]
14. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
Jenner P; Marsden CD
J Neural Transm Suppl; 1986; 20():11-39. PubMed ID: 3091760
[TBL] [Abstract][Full Text] [Related]
15. Granulocyte-macrophage colony-stimulating factor promotes survival of dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced murine Parkinson's disease model.
Kim NK; Choi BH; Huang X; Snyder BJ; Bukhari S; Kong TH; Park H; Park HC; Park SR; Ha Y
Eur J Neurosci; 2009 Mar; 29(5):891-900. PubMed ID: 19245369
[TBL] [Abstract][Full Text] [Related]
16. Alterations in dopamine uptake sites and D1 and D2 receptors in cats symptomatic for and recovered from experimental parkinsonism.
Frohna PA; Rothblat DS; Joyce JN; Schneider JS
Synapse; 1995 Jan; 19(1):46-55. PubMed ID: 7709343
[TBL] [Abstract][Full Text] [Related]
17. Alterations of the central noradrenergic system in MPTP-induced monkey parkinsonism.
Miyoshi R; Kito S; Ishida H; Katayama S
Res Commun Chem Pathol Pharmacol; 1988 Oct; 62(1):93-102. PubMed ID: 2849789
[TBL] [Abstract][Full Text] [Related]
18. Damage to the nigrostriatal system in the MPTP-treated SAMP8 mouse.
Liu J; Wang YY; Liu L; Wang QD; Yuan ZY; Zhang ZX; Gu P; Wang MW
Neurosci Lett; 2008 Dec; 448(2):184-8. PubMed ID: 18977411
[TBL] [Abstract][Full Text] [Related]
19. A new model to study compensatory mechanisms in MPTP-treated monkeys exhibiting recovery.
Mounayar S; Boulet S; Tandé D; Jan C; Pessiglione M; Hirsch EC; Féger J; Savasta M; François C; Tremblay L
Brain; 2007 Nov; 130(Pt 11):2898-914. PubMed ID: 17855373
[TBL] [Abstract][Full Text] [Related]
20. Long-lasting reactive changes observed in microglia in the striatal and substantia nigral of mice after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Yasuda Y; Shinagawa R; Yamada M; Mori T; Tateishi N; Fujita S
Brain Res; 2007 Mar; 1138():196-202. PubMed ID: 17275793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]